Drug Profile
Doxorubicin transferrin conjugate - Panther Biotechnology
Alternative Names: Doxorubicin transferrin conjugate - Faulk Pharmaceuticals; FP TD1; Transferrin Doxorubicin; TRF DOXLatest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator Faulk Pharmaceuticals
- Developer Panther Biotechnology
- Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Drug conjugates; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Ovarian cancer
Highest Development Phases
- Discontinued Haemangiosarcoma; Leukaemia; Ovarian cancer
Most Recent Events
- 25 Aug 2023 Discontinued - Clinical-Phase-Unknown for Haemangiosarcoma in USA (IV)
- 25 Aug 2023 Discontinued - Clinical-Phase-Unknown for Leukaemia in USA (IV)
- 25 Aug 2023 Discontinued - Clinical-Phase-Unknown for Ovarian cancer in USA (IV)